 |
|
|
| |
FAVOURABLE INCREASES IN HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) CONCENTRATIONS IN CHRONIC HIV-INFECTED THERAPY NAÏVE SUBJECTS RECEIVING 908/R QD IN THE SOLO STUDY
|
| |
| |
Reported by Jules Levin
Chronic HIV infection is associated with decreases in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and HDL-C. In HIV negative subjects, low HDL-C (<40mg/dL) and high TC/HDL-C ratios are associated with an increased risk for cardiovascular disease. Currently available protease inhibitors (PI) have often been associated with increases in TC and LDL-C (bad cholesterol) but little change in HDL-C (good cholesterol).
In SOLO, a 48-week randomised study, 322 subjects received 908/r QD (Fosamprenavir) (NFV: 327). Serum samples were collected in fasting state. Dyslipidemia was defined according to the US National Cholesterol Education Programme cut-offs.
At baseline (BL), the mean HDL-C level was 38mg/dL (NFV: 37mg/dL). After starting 908/r QD, mean HDL-C increased over 48 weeks to 46mg/dL (+ 29%; NFV: +27%). TC increased by 38% (NFV: +37%), but with minimal changes in TC/HDL-C ratio (mean +0.39; NFV: +0.34) observed.
|
|
| |
| |
| |
908/r QD |
908/r QD |
NFV BD |
NFV BD |
| |
n=232 |
n=245 |
| Observed Analysis |
BL |
Wk 48 |
BL |
Wk 48 |
| % w/HDL-C <40mg/dL |
60 |
25 |
68 |
31 |
| % w/HDL-C >40 |
36 |
61 |
28 |
51 |
| & below 60 |
| % w/HDL-C >60 |
4 |
15 |
4 |
18 |
| % e/TC/HDL-C ratio >6.5 |
15 |
18 |
9 |
14 |
|
|
| |
| |
The authors concluded that in this chronically HIV infected ART-naïve population with low baseline HDL-C, substantial increases in HDL-C combined with minimal changes in the TC/HDL-C ratio were observed following treatment with 908/r QD and NFV for 48-weeks. Similar observations were previously reported with NNRTIs.
Reference: 9TH EUROPEAN AIDS CONFERENCE (EACS), 1st EACS RESISTANCE & PHARMACOLOGY WORKSHOP, October 25 - 29, 2003 Warsaw, Poland. Oral Abstract F8/3 - FAVOURABLE INCREASES IN HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) CONCENTRATIONS IN CHRONIC HIV-INFECTED THERAPY NAÏVE SUBJECTS RECEIVING 908/R QD IN THE SOLO STUDY. Horban A. (1), Staszewski S. (2), Walmsley S. (3), Pierone G. (4), Sexton A. (5), Stark T. (6). (1) Hospital of Infectious Disease, Warsaw, Poland, (2) University Clinic Frankfurt/M, Germany, (3) University Health Network - Toronto General Hospital, Canada, (4) Treasure Coast Infectious Disease Consultants, Florida, USA, (5) GlaxoSmithKline R&D RTP, USA, (6) GlaxoSmithKline R&D, Greenford, UK
|
|
| |
|
|
|
|
|
